The Myasthenia Gravis drugs in development market research report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Myasthenia Gravis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued products.
GlobalData tracks 74 drugs in development for Myasthenia Gravis by 67 companies/universities/institutes. The top development phase for Myasthenia Gravis is preclinical with 27 drugs in that stage. The Myasthenia Gravis pipeline has 70 drugs in development by companies and four by universities/ institutes. Some of the companies in the Myasthenia Gravis pipeline products market are: Alexion Pharmaceuticals, Argenx and Cabaletta Bio.
The key targets in the Myasthenia Gravis pipeline products market include Complement C5, Tumor Necrosis Factor Receptor Superfamily Member 17, and B Lymphocyte Antigen CD19.
The key mechanisms of action in the Myasthenia Gravis pipeline product include Complement C5 Inhibitor with 15 drugs in Pre-Registration. The Myasthenia Gravis pipeline products include six routes of administration with the top ROA being Intravenous and 12 key molecule types in the Myasthenia Gravis pipeline products market including Monoclonal Antibody, and Gene-Modified Cell Therapy.
Myasthenia Gravis overview
Myasthenia gravis is an autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia, and difficulty swallowing, chewing, and speaking. Treatment includes immunosuppressants, corticosteroids, and surgery.
For a complete picture of Myasthenia Gravis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
